Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Jul;50(7):2917-2927.
doi: 10.1007/s00261-024-04729-3. Epub 2024 Dec 19.

International perspectives on LI-RADS

Affiliations
Review

International perspectives on LI-RADS

Andrea S Kierans et al. Abdom Radiol (NY). 2025 Jul.

Abstract

Given the crucial role of imaging in HCC diagnosis, LI-RADS CT/MRI was developed to standardize the imaging interpretation and reporting of HCC in patients at risk for HCC and categorize hepatic observations on an ordinal scale according to the likelihood of HCC. LI-RADS has since been expanded to include 5 algorithms: LI-RADS US Surveillance, contrast-enhanced US (CEUS) LI-RADS, LI-RADS CT/MRI, and LI-RADS Treatment Response Assessment. LI-RADS has been adopted broadly in North America, however with less ubiquitous adoption outside of North America. Further elucidation of the perceived strengths and weakness of the LI-RADS algorithm, as it pertains to various geographic regions, will continue to inform a future system that may be more readily adopted globally. Therefore, the aim of this article is to summarize HCC risk factors and imaging guidelines in select geographically disparate regions, and to solicit feedback from liver imaging experts on the limitations and barriers to adoption of LI-RADS algorithms in their patient populations.

Keywords: HCC; Hepatocellular carcinoma; LI-RADS; LI-RADS CT/MRI; LI-RADS International Working Group; LI-RADS US surveillance; LI-RADS treatment response.

PubMed Disclaimer

Conflict of interest statement

Declarations. Competing interests: The authors declare no competing interests.

References

    1. Villanueva A. Hepatocellular Carcinoma. N Engl J Med 2019;380(15):1450–1462. doi: https://doi.org/10.1056/NEJMra1713263 - DOI - PubMed
    1. Valery PC, Laversanne M, Clark PJ, Petrick JL, McGlynn KA, Bray F. Projections of primary liver cancer to 2030 in 30 countries worldwide. Hepatology 2018;67(2):600–611. doi: https://doi.org/10.1002/hep.29498 - DOI - PubMed
    1. Allaire M, Bruix J, Korenjak M, Manes S, Maravic Z, Reeves H, Salem R, Sangro B, Sherman M. What to do about hepatocellular carcinoma: Recommendations for health authorities from the International Liver Cancer Association. JHEP Rep 2022;4(12):100578. doi: https://doi.org/10.1016/j.jhepr.2022.100578 - DOI - PubMed - PMC
    1. Llovet JM, Kelley RK, Villanueva A, Singal AG, Pikarsky E, Roayaie S, Lencioni R, Koike K, Zucman-Rossi J, Finn RS. Hepatocellular carcinoma. Nat Rev Dis Primers 2021;7(1):6. doi: https://doi.org/10.1038/s41572-020-00240-3 - DOI - PubMed
    1. Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians 2024;74(3):229–263. doi: https://doi.org/10.3322/caac.21834 - DOI - PubMed